Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients With Paroxysmal and Persistent Atrial Fibrillation in Preventing Recurrent Episodes of Atrial Fibrillation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 125 participants.
Also called NCT02764619
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 125 participants
- Sponsor
- Registry
-
NCT02764619
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark
- Registry status
- Unknown status
Technical summary
Registry record NCT02764619. Randomized; quadruple masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2017-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients With Paroxysmal and Persistent Atrial Fibrillation in Preventing Recurrent Episodes of Atrial Fibrillation
- Acronym
- INSPIRE-AF
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Spironolactone
- Intervention (Drug)
- Placebo
- Lead sponsor
- Svendborg Hospital
- Collaborator
- Region of Southern Denmark
- Collaborator
- Takeda
Record details
- Record id
cardio:ct-nct02764619- Content hash
7cfb5348aeb620471d8a1c3077e1482bcd3e6a84174b3115c7cdba94a88d9b47